by Lancet Credit: Unsplash/CC0 Public Domain Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, according to the results of a randomized controlled trial, published in The Lancetjournal. However, the patients treated at home with...
Tag: <span>Molnupiravir</span>
Post
Merck’s Covid pill hailed after cutting hospitalizations by 50%
Capsules of the experimental antiviral drug Molnupiravir. Pharmaceutical company Merck said Friday it will seek authorization in the US of its oral drug molnupiravir for COVID-19 after it was shown to reduce the chance newly infected patients were hospitalized by 50 percent. A simple pill to treat the coronavirus has been sought since the start...